{{Rsnum
|rsid=986475
|Gene=NCR3
|Chromosome=6
|position=31588932
|Orientation=minus
|GMAF=0.1033
|Gene_s=LST1,NCR3
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 11.5 | 88.5
| HCB | 2.9 | 29.2 | 67.9
| JPT | 5.3 | 30.1 | 64.6
| YRI | 0.0 | 5.4 | 94.6
| ASW | 0.0 | 8.8 | 91.2
| CHB | 2.9 | 29.2 | 67.9
| CHD | 1.8 | 26.6 | 71.6
| GIH | 3.0 | 15.8 | 81.2
| LWK | 0.0 | 1.8 | 98.2
| MEX | 1.7 | 39.7 | 58.6
| MKK | 0.0 | 0.6 | 99.4
| TSI | 1.0 | 25.5 | 73.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs986475
|Name_s=
|Gene_s=LTB, NCR3, LST1
|Feature=
|Evidence=PubMed ID:16538176
|Annotation=Risk or phenotype-associated allele: C allele. Phenotype: Carbamazepine (CBZ)-induced maculopapular exanthema (MPE). Study size: 162. Study population/ethnicity: 18 CBZ-induced MPE cases and 144 CBZ-tolerant controls of Chinese descent. Significance metric(s): p = 0.007597, OR = 3.19. Type of association: GN; PD; TOX; ADR.
|Drugs=carbamazepine
|Drug Classes=
|Diseases=Drug Hypersensitivity; Exanthema; Maculopapular Exanthema
|Curation Level=Curated
|PharmGKB Accession ID=PA165291967
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs986475
|overall_frequency_n=9
|overall_frequency_d=128
|overall_frequency=0.0703125
|n_genomes=9
|n_genomes_annotated=0
|n_haplomes=9
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=2
|webscore=N
|n_web_uneval=10
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}